Cargando…
Sarcopenia and Muscle Aging: A Brief Overview
The world is facing the new challenges of an aging population, and understanding the process of aging has therefore become one of the most important global concerns. Sarcopenia is a condition which is defined by the gradual loss of skeletal muscle mass and function with age. In research and clinical...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Endocrine Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803599/ https://www.ncbi.nlm.nih.gov/pubmed/33397034 http://dx.doi.org/10.3803/EnM.2020.405 |
_version_ | 1783635975546601472 |
---|---|
author | Dao, Tam Green, Alexander E. Kim, Yun A Bae, Sung-Jin Ha, Ki-Tae Gariani, Karim Lee, Mi-ra Menzies, Keir J. Ryu, Dongryeol |
author_facet | Dao, Tam Green, Alexander E. Kim, Yun A Bae, Sung-Jin Ha, Ki-Tae Gariani, Karim Lee, Mi-ra Menzies, Keir J. Ryu, Dongryeol |
author_sort | Dao, Tam |
collection | PubMed |
description | The world is facing the new challenges of an aging population, and understanding the process of aging has therefore become one of the most important global concerns. Sarcopenia is a condition which is defined by the gradual loss of skeletal muscle mass and function with age. In research and clinical practice, sarcopenia is recognized as a component of geriatric disease and is a current target for drug development. In this review we define this condition and provide an overview of current therapeutic approaches. We further highlight recent findings that describe key pathophysiological phenotypes of this condition, including alterations in muscle fiber types, mitochondrial function, nicotinamide adenine dinucleotide (NAD(+)) metabolism, myokines, and gut microbiota, in aged muscle compared to young muscle or healthy aged muscle. The last part of this review examines new therapeutic avenues for promising treatment targets. There is still no accepted therapy for sarcopenia in humans. Here we provide a brief review of the current state of research derived from various mouse models or human samples that provide novel routes for the development of effective therapeutics to maintain muscle health during aging. |
format | Online Article Text |
id | pubmed-7803599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Korean Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-78035992021-01-22 Sarcopenia and Muscle Aging: A Brief Overview Dao, Tam Green, Alexander E. Kim, Yun A Bae, Sung-Jin Ha, Ki-Tae Gariani, Karim Lee, Mi-ra Menzies, Keir J. Ryu, Dongryeol Endocrinol Metab (Seoul) Review Article The world is facing the new challenges of an aging population, and understanding the process of aging has therefore become one of the most important global concerns. Sarcopenia is a condition which is defined by the gradual loss of skeletal muscle mass and function with age. In research and clinical practice, sarcopenia is recognized as a component of geriatric disease and is a current target for drug development. In this review we define this condition and provide an overview of current therapeutic approaches. We further highlight recent findings that describe key pathophysiological phenotypes of this condition, including alterations in muscle fiber types, mitochondrial function, nicotinamide adenine dinucleotide (NAD(+)) metabolism, myokines, and gut microbiota, in aged muscle compared to young muscle or healthy aged muscle. The last part of this review examines new therapeutic avenues for promising treatment targets. There is still no accepted therapy for sarcopenia in humans. Here we provide a brief review of the current state of research derived from various mouse models or human samples that provide novel routes for the development of effective therapeutics to maintain muscle health during aging. Korean Endocrine Society 2020-12 2020-12-31 /pmc/articles/PMC7803599/ /pubmed/33397034 http://dx.doi.org/10.3803/EnM.2020.405 Text en Copyright © 2020 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Dao, Tam Green, Alexander E. Kim, Yun A Bae, Sung-Jin Ha, Ki-Tae Gariani, Karim Lee, Mi-ra Menzies, Keir J. Ryu, Dongryeol Sarcopenia and Muscle Aging: A Brief Overview |
title | Sarcopenia and Muscle Aging: A Brief Overview |
title_full | Sarcopenia and Muscle Aging: A Brief Overview |
title_fullStr | Sarcopenia and Muscle Aging: A Brief Overview |
title_full_unstemmed | Sarcopenia and Muscle Aging: A Brief Overview |
title_short | Sarcopenia and Muscle Aging: A Brief Overview |
title_sort | sarcopenia and muscle aging: a brief overview |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803599/ https://www.ncbi.nlm.nih.gov/pubmed/33397034 http://dx.doi.org/10.3803/EnM.2020.405 |
work_keys_str_mv | AT daotam sarcopeniaandmuscleagingabriefoverview AT greenalexandere sarcopeniaandmuscleagingabriefoverview AT kimyuna sarcopeniaandmuscleagingabriefoverview AT baesungjin sarcopeniaandmuscleagingabriefoverview AT hakitae sarcopeniaandmuscleagingabriefoverview AT garianikarim sarcopeniaandmuscleagingabriefoverview AT leemira sarcopeniaandmuscleagingabriefoverview AT menzieskeirj sarcopeniaandmuscleagingabriefoverview AT ryudongryeol sarcopeniaandmuscleagingabriefoverview |